| Date | Title | Description |
| 22.10.2024 | OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC INITIÉE PAR LA SOCIÉTÉ EB DEVELOPMENT - Communiqué de mise à disposition du public de la note en réponse de la société Eurobi... | COMMUNIQUÉ DU 22 OCTOBRE 2024
OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC
INITIÉE PAR LA SOCIÉTÉ EB DEVELOPMENT
AGISSANT DE CONCERT AVEC IK X LUXCO 3 S.A R.L, EUROBIONEXT, FPCI PEPITES ET TERRITOIRES, NEXTSTAG... |
| 22.10.2024 | Eurobio Scientific: COMMUNIQUÉ DU 22 OCTOBRE 2024 RELATIF À LA MISE À DISPOSITION DE LA NOTE D’INFORMATION DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC... | COMMUNIQUÉ DU 22 OCTOBRE 2024
RELATIF À LA MISE À DISPOSITION DE LA NOTE D’INFORMATION
DANS LE CADRE DE L’OFFRE PUBLIQUE D’ACHAT VISANT LES ACTIONS DE LA SOCIÉTÉ EUROBIO SCIENTIFIC
INITIÉE PAR
EB DEVELOPMENT
AGISSANT DE CONCERT AVEC IK X LU... |
| 24.09.2024 | Eurobio Scientific: RESULTS FOR THE 1ST HALF OF 2024 | RESULTS FOR THE 1ST HALF OF 2024 Revenues up 12% on a like-for-like basis (24% overall)Stable adjusted EBITDA1 and operating profitNet financial debt down slightly to €1.6m, with cash of €86.6mProposed voluntary takeover bid
Paris, Septembe... |
| 02.08.2024 | EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS | EUROBIO SCIENTIFIC COMPLETES ACQUISITION OF ENDOPREDICT® GENOMIC TEST FROM MYRIAD GENETICS
Paris, August 2nd, 2024 –7:30 am
Eurobio Scientific (FR0013240934, ALERS), a leading French group in in vitro specialty medical diagnostics and life ... |
| 01.08.2024 | Eurobio Scientific : suspension du contrat de liquidité | EUROBIO SCIENTIFIC : SUSPENSION DU CONTRAT DE LIQUIDITÉ
Paris, le 1er août 2024 – 17h45
Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro et les sciences de la vie, annonc... |
| 31.07.2024 | Eurobio Scientific: FIRST HALF 2024, A SOLID START TO THE FINANCIAL YEAR IN AN UNCERTAIN ENVIRONMENT // PROPOSED TENDER OFFER | NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.
FIRST HAL... |
| 31.07.2024 | EUROBIO SCIENTIFIC: CONCLUSION OF AN AGREEMENT BETWEEN EUROBIO SCIENTIFIC AND A CONSORTIUM LED BY EUROBIO SCIENTIFIC'S TEAM OF ENTREPRENEURS AND MANAGERS, IK PARTNERS AND NEXTSTAGE AM WITH A VIEW TO F... | NOT FOR DISTRIBUTION, PUBLICATION OR RELEASE, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES OR TO ANY US PERSON, OR TO ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION, PUBLICATION OR RELEASE WOULD BE UNLAWFUL.
CONCLUSIO... |
| 23.07.2024 | EUROBIO SCIENTIFIC : CALENDRIER DES PUBLICATIONS FINANCIÈRES DU 2EME SEMESTRE | CALENDRIER DES PUBLICATIONS FINANCIÈRES DU 2EME SEMESTRE
Paris, le 23 juillet 2024 - 11h30 - Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro et les sciences de la vie, p... |
| 03.07.2024 | Eurobio Scientific : bilan semestriel du contrat de liquidité | BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Paris, le 3 juillet 2024 –17h45
Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe), les moyens suivants figu... |
| 27.10.2022 | EUROBIO : MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2022 | MISE À DISPOSITION DU RAPPORT FINANCIER SEMESTRIEL 2022
Paris, le 27 octobre 2022 – 18h00
Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mi... |
| 11.10.2022 | EUROBIO SCIENTIFIC: H1 2022 RESULTS CONTINUED GROWTH OF NON-COVID ACTIVITY | H1 2022 RESULTS
CONTINUED GROWTH OF NON-COVID ACTIVITY
• Decisive and strategic move with the acquisitions of GenDx and bmd Belgium
• Non-COVID activity increases by +5.1%
• +€26M EBITDA including significant provisions on COVID products
• ... |
| 03.10.2022 | EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST | EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF GENDX,
INTERNATIONAL HLA DIAGNOSTICS SPECIALIST
• Acceleration of strategic plan confirming its positioning as a leader in the molecular diagnostics market
• Acquisition of a 100% proprietary ... |
| 19.08.2022 | Eurobio Scientific buys Dutch transplant diagnostics firm GenDx for €135 million | The Netherlands-based startup that offers molecular diagnostic kits Genome Diagnostics (GenDx) has been acquired by Paris-based Eurobio Scientific for €135 million. The acquisition will lead to the formation of a foundation to assist resear... |
| 17.08.2022 | EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENDX, INTERNATIONAL HLA DIAGNOSTICS SPECIALIST | EUROBIO SCIENTIFIC SIGNS AN AGREEMENT TO ACQUIRE GENDX,
INTERNATIONAL HLA DIAGNOSTICS SPECIALIST
• Acceleration of strategic plan confirming its positioning as a leader in the molecular diagnostics market
• Acquisition of a 100% proprietary... |
| 11.07.2022 | EUROBIO SCIENTIFIC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE | BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Paris, le 11 juillet 2022 –8h00
Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe), les moyens suivants figu... |
| 14.06.2022 | ASSEMBLEE GENERALE ORDINAIRE ET EXTRAORDINAIRE D’EUROBIO SCIENTIFIC | ASSEMBLEE GENERALE ORDINAIRE ET EXTRAORDINAIRE
D’EUROBIO SCIENTIFIC
Les actionnaires ont adopté toutes les résolutions à titre ordinaire et extraordinaire agréées par le conseil d’administration
Paris, le 14 juin 2022 –8h00
Eurobio Scientif... |
| 28.04.2022 | EUROBIO SCIENTIFIC : MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2021 | MISE À DISPOSITION DU RAPPORT FINANCIER ANNUEL 2021
Paris, le 28 avril 2022 – 22h45
Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro de spécialité, annonce avoir mis à di... |
| 10.01.2022 | EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME | EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE
AU DISPOSITIF PEA-PME
Paris, le 10 janvier 2022 – 17h45
Eurobio Scientific (FR0013240934, ALERS, éligible PEA-PME), groupe français leader dans le diagnostic médical in vitro et les sciences de la... |
| 04.01.2022 | EUROBIO SCIENTIFIC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE | BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Paris, le 4 janvier 2022 –17h45
Au titre du contrat de liquidité portant sur les actions de la société EUROBIO SCIENTIFIC (FR0013240934 – ALERS FP) confié à TP ICAP (Europe), les moyens suivants figu... |
| 23.11.2021 | Eurobio Scientific : makes a minority investment in Usense | PRESSRELEASE
EUROBIO SCIENTIFIC MAKES A MINORITY INVESTMENT IN USENSE, A START-UP DEVELOPPING A MOBILE IN VITRO MEDICAL DEVICE FOR URIANALYSIS
With this investment, the Group strengthens its offer in point of care medical biology and
positi... |
| 06.10.2021 | Eurobio Scientific : Receives a $430,000 Milestone Payment From Allergan | EUROBIO SCIENTIFIC RECEIVES A $430,000 MILESTONE PAYMENT FROM ALLERGAN
Transition to clinical stage of a molecule derived from the former collaboration
Paris, October 6, 2021 – 8:00 am
Eurobio Scientific (FR0013240934, ALERS, eligible PEA-P... |
| 06.10.2021 | Eurobio Scientific Receives a $430,000 Milestone Payment From Allergan | EUROBIO SCIENTIFIC RECEIVES A $430,000 MILESTONE PAYMENT FROM ALLERGAN
Transition to clinical stage of a molecule derived from the former collaboration
Paris, October 6, 2021 – 8:00 am
Eurobio Scientific (FR0013240934, ALERS, eligible PEA-P... |
| 26.05.2021 | EUROBIO SCIENTIFIC
Eurobio Scientific : launches a new proprietary test for simultaneous detection of the SARS-CoV-2 virus and characterization of its new mutations | PRESSRELEASE
Eurobio Scientific offers a new proprietary test for simultaneous detection of the SARS-CoV-2 virus and characterization of its new mutations of interest
Paris, May 26, 2021 - 7:30 am
Eurobio Scientific (FR0013240934, ALERS, PE... |
| 29.04.2021 | Eurobio Scientific : Exceptional 2020 results | PRESS RELEASE
EXCEPTIONAL 2020 RESULTS
EBITDA : € 88.2m (x12.6)
Net income : € 73.5m (x23)
Consolidation of a new dimension for the Group
Paris, April 29, 2021 5:45 pm
Eurobio Scientific (FR0013240934, ALERS, PEA-PMEeligible), a leading Fre... |
